Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PemCiGem: Pembrolizumab with Cisplatin and Gemcitabine in Recurrent Platinum-Resistant Ovarian Cancer
NCT02608684Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Feb 2016
- Primary completion
- May 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in ovarian cancer, sponsored by Cedars-Sinai Medical Center. Primary endpoint: Overall Response Rate at 2 years. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02608684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608684.